Cited 85 times in
A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.